日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

scFv intrabody targeting wildtype TDP-43 presents protective effects in a cellular model of TDP-43 proteinopathy.

靶向野生型 TDP-43 的 scFv 胞内抗体在 TDP-43 蛋白病细胞模型中表现出保护作用

Al Ojaimi Yara, Hergesheimer Rudolf, Chami Anna A, Alarcan Hugo, Augros Johanna, Dangoumau Audrey, Haouari Shanez, Bourgeais Jérôme, Lefevre Antoine, Osman Samira, Emond Patrick, Vourc'h Patrick, Andres Christian R, Corcia Philippe, Herault Olivier, Martineau Pierre, Lanznaster Débora, Blasco Hélène

Therapeutic antibodies - natural and pathological barriers and strategies to overcome them

治疗性抗体——天然和病理屏障及克服策略

Al Ojaimi, Yara; Blin, Timothée; Lamamy, Juliette; Gracia, Matthieu; Pitiot, Aubin; Denevault-Sabourin, Caroline; Joubert, Nicolas; Pouget, Jean-Pierre; Gouilleux-Gruart, Valérie; Heuzé-Vourc'h, Nathalie; Lanznaster, Débora; Poty, Sophie; Sécher, Thomas

Taking Advantages of Blood-Brain or Spinal Cord Barrier Alterations or Restoring Them to Optimize Therapy in ALS?

利用血脑屏障或脊髓屏障的改变或恢复这些改变来优化ALS的治疗?

Alarcan, Hugo; Al Ojaimi, Yara; Lanznaster, Debora; Escoffre, Jean-Michel; Corcia, Philippe; Vourc'h, Patrick; Andres, Christian R; Veyrat-Durebex, Charlotte; Blasco, Hélène